Abstract:Background Tumors are characterized by extracellular matrix (ECM) remodeling and stiffening. The ECM has been recognized as an important determinant of breast cancer progression and prognosis. Recent studies have revealed a strong link between ECM remodeling and immune cell infiltration in a variety of tumor types. However, the landscape and specific regulatory mechanisms between ECM and immune microenvironment in breast cancer have not been fully understood. Methods Using genomic data and clinical information of breast cancer patients obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we conducted an extensive multi-omics analysis to explore the heterogeneity and prognostic significance of the ECM microenvironment. Masson and Sirius red staining were applied to quantify the contents of collagen in the ECM microenvironment. Tissue immunofluorescence (IF) staining was applied to identify T helper (Th) cells. Results We classified breast cancer patients into two ECM-clusters and three gene-clusters by consensus clustering. Significant heterogeneity in prognosis and immune cell infiltration have been found in these distinct clusters. Specifically, in the ECM-cluster with better prognosis, the expression levels of Th2 and regulatory T (Treg) cells were reduced, while the Th1, Th17 and T follicular helper (Tfh) cells-associated activities were significantly enhanced. The correlations between ECM characteristics and Th cells infiltration were then validated by clinical tissue samples from our hospital. The ECM-associated prognostic model was then constructed by 10 core prognostic genes and stratified breast cancer patients into two risk groups. Kaplan-Meier analysis showed that the overall survival (OS) of breast cancer patients in the high-risk group was significantly worse than that of the low-risk group. The risk scores for breast cancer patients obtained from our prognostic model were further confirmed to be associated with immune cell infiltration, tumor mutation burden (TMB) and stem cell indexes. Finally, the half-maximal inhibitory concentration (IC50) values of antitumor agents for patients in different risk groups were calculated to provide references for therapy targeting distinct ECM characteristics. Conclusion Our findings identify a novel strategy for breast cancer subtyping based on the ECM characterization and reveal the regulatory roles of Th cells in ECM remodeling. Targeting ECM remodeling and Th cells hold potential to be a therapeutic alternative for breast cancer in the future.

Extracellular matrix remodeling in the tumor immunity

Extracellular matrix and its therapeutic potential for cancer treatment

Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer

Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment

Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?

The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis

Targeting Extracellular Matrix Interaction in Gastrointestinal Cancer: Immune Modulation, Metabolic Reprogramming, and Therapeutic Strategies

The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis

Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy

The regulatory roles of T helper cells in distinct extracellular matrix characterization in breast cancer

Biomaterials to regulate tumor extracellular matrix in immunotherapy

The extracellular matrix in solid tumor immunotherapy

The Matrix Reloaded—The Role of the Extracellular Matrix in Cancer

Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

Extracellular Matrix in Mammary Gland Development and Breast Cancer Progression

The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?

Understanding the matrix: collagen modifications in tumors and their implications for immunotherapy

Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy

The Role of Extracellular Matrix Proteins in Breast Cancer